- Oppenheimer said that a new analysis conducted by Veru ( NASDAQ: VERU ) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an Emergency Use Authorization from the U.S. FDA.
- The firm cited a new corporate presentation in making its call.
- The document indicates that the primary endpoint -- mortality rate by day 60 -- was met. In the treatment group, it was 20.2%, while in the placebo group, 45.1%.
- Sabizabulin also met second efficacy endpoints compared to placebo in terms of days in the ICU, on mechanical ventilation, and in the hospital.
- Read what Jefferies had to say in July about the prospects for sabizabulin .
For further details see:
Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer